£1 million award for BactiVac network to continue supporting development of bacterial vaccines
22 February 2023
Bacterial infections kill over 7 million people each year and the development of new and better vaccines will reduce this devastating burden of disease.
BactiVac, the Bacterial Vaccines Network, has secured £1 million of funding from Wellcome to accelerate the development of bacterial vaccines and combat the threat of antimicrobial resistance (AMR).
Further reading: University of Birmingham
Author(s): University of Birmingham
Effective Surveillance
OUR UNDERWRITERS
Unrestricted financial support by:
 |
Antimicrobial Resistance Fighter Coalition |
 |
Evotec |
 |
JSS University |
 |
INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS |
Technology Database
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.
